Primecap Management Co. CA Buys 22,600 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Primecap Management Co. CA grew its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,520,630 shares of the company’s stock after purchasing an additional 22,600 shares during the quarter. Primecap Management Co. CA’s holdings in Zentalis Pharmaceuticals were worth $4,608,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ZNTL. Barclays PLC grew its stake in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares in the last quarter. Verition Fund Management LLC grew its position in shares of Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after buying an additional 951,500 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after buying an additional 30,240 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 126.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after acquiring an additional 127,868 shares in the last quarter. Finally, Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter worth about $72,000.

Insider Transactions at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $1.79 on Thursday. The business’s 50-day moving average is $2.14 and its 200 day moving average is $2.92. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.61 and a 1 year high of $16.27. The firm has a market capitalization of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Wells Fargo & Company reduced their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday. Finally, UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.